Molecularly, most primary GBMs lack mutations in isocitrate dehydrogenase (IDH) genes that differentiate them from lower-grade gliomas and secondary GBMs with IDH mutations [3,5,27]. The gene discussed is IDH2; the disease is central nervous system cancer.